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Abstract 34 
 35 
Introduction: Based on international guidelines, axillary lymph node dissection (ALND) is 36 
recommended in cases of breast cancer if preoperative examinations confirm axillary 37 
metastasis. We examined which set of preoperative parameters might render ALND 38 
unnecessary. 39 
Patients and methods: Preoperative examinations (axillary ultrasound and aspiration cytology) 40 
confirmed axillary metastasis in 190 cases out of 2671 patients with breast cancer; primary 41 
ALN dissection was performed on these patients with or without prior neoadjuvant therapy. 42 
The clinicopathological results were analysed to determine which parameter might predict the 43 
presence of no more than 2 or 3 metastatic ALNs. 44 
Results: The final histological examination confirmed 1–3 metastatic lymph nodes in ALND 45 
samples in 116 cases and over 3 metastatic lymph nodes in 74 cases. 46 
For patients receiving neoadjuvant therapy (59 out of the 190 cases), if the size of the primary 47 
tumour was 2 cm or smaller and/or the metastatic ALN was 15 mm or smaller, then the patient 48 
was likely to have no more than 3 positive ALNs (stage N0–1 disease) (p < 0.001). If the patient 49 
did not receive neoadjuvant therapy, stage N2 or N3 disease was very likely. No correlation 50 
was found between other clinicopathological characteristics of the tumour and involvement of 51 
the ALNs. 52 
Conclusion: Axillary lymph node dissection is not necessary for selected breast cancer patients 53 
with axillary metastasis receiving neoadjuvant therapy. In these cases, sentinel lymph node 54 
biopsy with or without radiation therapy and close follow-up may serve as adequate therapy. 55 
 56 
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Introduction 59 
Surgical treatment of patients with breast cancer and positive axillary lymph nodes is 60 
becoming less and less invasive. In the background, it would have been better to mention which 61 
are known high risk features that mandate ALND: The clinically node-positive axilla, 62 
confirmed by fine needle aspiration or core biopsy, in a patient for whom neoadjuvant 63 
chemotherapy is not planned. Occult breast cancer presenting as axillary node metastasis. SLN 64 
positive patients who fall outside the Z0011 selection criteria (i.e. >2 SLN positive, matted 65 
nodes, mastectomy, or breast conservation without whole-breast radiotherapy). Inflammatory, 66 
clinical stage T4, or high-risk T3 breast cancer. Failed SLN mapping. Inadequate prior ALND 67 
with residual clinically suspicious nodes Sentinel or axillary nodes which remain positive after 68 
neoadjuvant chemotherapy. Axillary recurrence following previous breast cancer treatment. 69 
Based on results from the ACOSOG Z0011 study, axillary lymph node dissection 70 
(ALND) is not required even in cases with 1 or 2 axillary sentinel lymph nodes involving 71 
macrometastasis if the patient meets the inclusion criteria for the study.1,2 This recommendation 72 
has been approved by international and Hungarian consensus conferences as well.3,4 73 
Patients with ALN metastasis confirmed by preoperative examinations represent a 74 
separate treatment group. ALND must be performed on these patients if surgical treatment is 75 
required. Axillary ultrasound is a key method for diagnosing axillary metastasis, and a positive 76 
axillary ultrasound result also necessitates aspiration cytology. Sensitivity of axillary ultrasound 77 
ranges from 25 to 71% depending on the immunohistochemical status of the tumour5; 78 
sensitivity increases to approximately 70 to 80% with the addition of fine needle aspiration 79 
cytology (FNAC). 6,7,8,9 80 
In cases where a lymph node is found to be positive with aspiration cytology, systemic 81 
neoadjuvant therapy is performed on some patients. Based on international results, complete 82 
axillary pathological regression occurs in a significant portion of these patients.10,11,12 83 
Two major prospective study has investigated SLNB after NAC: the SAKK 23/16 84 
TAXIS trial and the ALLIANCE A011202 trial. 85 
Similarly, we know that in a portion of patients, metastasis is only present in the sentinel 86 
lymph node. A study published in 2017 confirmed that axillary lymph node dissection is may 87 
not necessarily indicated as the first surgery; sentinel lymph node biopsy (SLNB) is 88 
recommended instead if the primary tumour is ≤2 cm as confirmed by a preoperative breast 89 
ultrasound examination, no more than one lymph node in the axillary region is confirmed 90 
positive with aspiration cytology, and the patient does not receive neoadjuvant therapy.13 91 
Therefore, in our study, we were looking for correlations between the preoperative 92 
axillary ultrasound examination and clinicopathological factors to be able to predict not only 93 
the presence, but also the severity of axillary metastasis (slight or severe). A further aim of our 94 
study was to decide in advance when ALND is required and in which cases SLNB is sufficient 95 
based on the results of preoperative examinations. 96 
 97 
Patients and methods 98 
Pre- and postoperative data from 2671 cases where surgery was performed due to early 99 
invasive breast tumour were evaluated in the Department of Surgery, Faculty of Medicine, 100 
University of Szeged between 1 January 2007 and 31 December 2017. Mandatory items of the 101 
complex breast examination included a physical examination, an ultrasound examination, a 102 
mammogram and histology. This was a retrospective analysis of a prospectively maintained 103 
database. 104 
Both axilla examined - axilla level 1,2,3 included- during the axillary US. All the 105 
enlarged and abnormal lymph nodes have to be recorded in the description. Axillary ultrasound 106 
was considered positive if the eccentric or concentric cortical region of the lymph node was 107 
larger than 2.5 mm, the adipose hilum was missing, the lymph node was morphologically 108 
rounded, or its blood supply was increased. In cases where axillary ultrasound and aspiration 109 
cytology were positive, neoadjuvant systemic therapy was also administered in some patients. 110 
Neoadjuvant therapy was administered in accordance with current international practice, 111 
primarily to be able to remove tumours originally found to be oncologically inoperable and to 112 
be able to perform breast-conserving surgery instead of a mastectomy. 113 
Surgical treatment: our goal was to provide locoregional tumour control and precise 114 
locoregional staging. With an aesthetic outcome also taken into consideration, breast-115 
conserving surgery was performed whenever possible. ROLL (radio-guided occult lesion 116 
localisation) and dual labelling were used to localise breast tumours and the sentinel lymph 117 
node.  At least 4 hours before the surgery, isotope (99mTc) labelled human colloidal albumin 118 
was administered into the lesion, which was followed by lymphoscintigraphy to determine the 119 
projection of the sentinel lymph node and that of the lymphatic drainage. As a first step during 120 
surgery, Patentblau dye was administered around the areola, and then manual gamma probe 121 
was used to remove the tumour and the sentinel lymph node(s) during the same procedure 122 
approximately 10 minutes later. ALND was primarily performed with or without prior 123 
neoadjuvant therapy if preoperative examinations confirmed the presence of even one axillary 124 
lymph node metastasis. 125 
Patients were divided into two large groups on the basis of a final histological 126 
examination of the axillary lymph nodes. One group consisted of patients with no more than 127 
3 positive lymph nodes (N0–1) in accordance with the TNM classification; the other group 128 
consisted of patients with 4 or more positive lymph nodes (N2–3). Due to the maximum of 129 
2 positive lymph nodes described in the Z0011 study, we formed an additional group with no 130 
more than 2 metastatic lymph nodes (Z1) and another with 3 or more metastatic lymph nodes 131 
(Z2). The clinical, radiological and histological results of these groups were analysed as well. 132 
In our study, clinicopathological results (histological and immunohistochemical status, 133 
tumour location, tumour size before and after surgery, size and number of abnormal lymph 134 
nodes described by ultrasound examination, cytology of the axillary lymph node, neoadjuvant 135 
therapy and final axillary histological lymph node status) were compared. We aimed to 136 
ascertain which preoperative examination results may be used to predict the presence of a 137 
maximum of only 2 or 3 metastatic lymph nodes in the axillary region. 138 
Statistics IBM SPSS Statistics v22 software was used for statistical analysis in our study. 139 
Continuous variables were presented as mean and standard deviation, while categorical 140 
variables were presented as case number and percentages. The chi square test followed by 141 
logistic regression was used to evaluate the cumulative effect of the variables on axillary status. 142 
The difference was considered statistically significant in cases where p < 0.05 with 95% 143 
confidence interval. 144 
 145 
Results 146 
Surgical intervention was performed in 2671 invasive breast tumour cases (average age: 147 
59.73 years). In 260 cases, axillary ultrasound suggested a metastatic lymph node; therefore, 148 
aspiration cytology sampling was performed. In 190 cases, pathology reports suggested 149 
metastasis; in these cases, ALND was performed. The average number of lymph nodes removed 150 
was 13.49. 151 
False positive results were found in 11 (8.4%) of the 131 aspiration cytology 152 
examinations in patients not receiving neoadjuvant therapy. Based on a final histological 153 
examination of the ALNs, 76 (58%) patients were confirmed to be stage N0–1 and 55 (42%) 154 
patients were stage N2–3. 155 
No significant correlation was found between preoperatively assessable 156 
clinicopathological parameters and axillary lymph node status for patients not receiving 157 
neoadjuvant therapy (Tables 1 and 2). 158 
Neoadjuvant therapy was administered in 59 cases, and in 23 (39%) of these cases, 159 
complete axillary pathological remission was confirmed. Based on a final histological 160 
examination of the axillary lymph nodes, 40 (68%) patients were in stage N0–1 and 19 (32%) 161 
patients were in stage N2–3. 162 
The results of the histological examinations, the immunohistochemical status and the 163 
number of positive lymph nodes detected by ultrasound examination showed no correlation to 164 
the final histological status of the lymph node. If preoperative ultrasound examinations find that 165 
the primary breast tumour is ≤20 mm (p = 0.002) or the positive lymph node is ≤15 mm 166 
(p = 0.04), the status of the axillary lymph nodes will likely be stage N0–1; therefore, a 167 
maximum of 3 positive axillary lymph nodes are present (Tables 3 and 4). 168 
In patients with TNBC (triple negative breast cancer) who receiving neoadjuvant 169 
therapy if the size of the tumour is ≤20 mm based on the ultrasound examination is no more 170 
than 3 metastatic lymph nodes (N1, p<0.001) (Table 3).  171 
We examined the likelihood of stage N0–1 in the presence of two preoperative factors: 172 
≤20 mm tumour size as measured by ultrasound and a ≤15 mm size of the lymph node 173 
considered metastatic. In the patient group not receiving neoadjuvant therapy (p = 0.948), this 174 
could not be confirmed; however, in patients receiving neoadjuvant therapy, the likelihood of 175 
no more than 3 metastatic lymph nodes is very high (p = 0.01). 176 
Logistic regression was used to examine which variables are predictive of axillary 177 
status. Using the omnibus test, we found that the independent variables in the model are more 178 
related to the dependent variable than we would expect due to chance (p < 0.001). We were 179 
able to confirm that the size of the tumour (Exp (B) = 1.050, 95% CI = 1.016–1.085, p = 0.004) 180 
is predictive of axillary status. The resulting model was statistically significant (χ2 = 18.806, 181 
df = 3, p < 0.001). The proportion of cases categorized correctly was 69.4% (overall percentage) 182 
with this model, leading to a more precise result compared to categorizing by chance (55.4%) 183 
(Table 5). 184 
Cases with no more than 2 (Z1) or 3 or more lymph nodes (Z2) were compared to the 185 
preoperatively assessable factors in patients grouped by receiving or not receiving neoadjuvant 186 
therapy. In patients not receiving neoadjuvant therapy, the size of the breast tumour, axillary 187 
status and clinicopathological characteristics of the tumour showed no correlation to the final 188 
histological status of the axilla (data not shown). 189 
In patients receiving neoadjuvant therapy, the possibility of no more than 2 metastatic 190 
lymph nodes is very high if the size of the tumour is ≤20 mm (p = 0.008) based on the ultrasound 191 
examination and this is higher in patients with TNBC (p=0.002). The joint presence of two 192 
preoperatively assessable factors – ≤20 mm tumour size confirmed by ultrasound and a <15 mm 193 
size of the lymph node considered metastatic – only increased the possibility of no more than 194 
2 positive lymph nodes in patients receiving neoadjuvant therapy (p = 0.728 vs. p = 0.017) 195 
(Table 6).  196 
The final lymph node status of the axilla showed no relation to other clinicopathological 197 
characteristics (data not shown). 198 
 199 
Discussion  200 
ALND has been the standard procedure in the surgical treatment of malignant breast 201 
tumours for at least 100 years, with significant changes occurring in recent years. SLNB14 can 202 
be used to avoid ALND in a significant proportion of patients; therefore, morbidity of surgical 203 
treatment of early breast cancers can be decreased significantly.15,16,17 At first, if preoperative 204 
examinations found no metastasis but the intraoperative or final histological examination 205 
confirmed metastasis in the SLN, ALND was considered necessary. Later, clinical studies 206 
confirmed that even the presence of micrometastasis or an isolated tumour cell in a lymph node 207 
is sufficient to indicate SLNB.18,19 The result of the ACOSOG Z0011 study was a milestone. 208 
This study concluded that even in cases with a maximum of two positive lymph nodes 209 
containing macrometastasis, ALND may be avoided if the patient meets the inclusion criteria 210 
for the study.1,2 Moreover, based on the results of the AMAROS study, ALND may also be 211 
avoided in patients who have undergone a mastectomy and have a SLN with confirmed 212 
metastasis; irradiation of the axillary region and close follow-up are sufficient.20 213 
Nowadays, the effort to further limit the indication area of ALND accompanied by 214 
significant morbidity is completely reasonable. One way to do this is to preoperatively screen 215 
patients only at stage N1 axillary status. Based on several international guidelines, a sentinel 216 
lymph node biopsy should be performed in cases characterised by the presence of axillary 217 
lymph nodes considered negative by preoperative examinations and aspiration cytology or core 218 
biopsy should be performed with axillary lymph nodes considered positive.3,4,21,22 Several 219 
research groups have studied which factors detected or examined during the preoperative period 220 
(imaging studies, histological finding etc.) may be suitable to determine whether SLNB or 221 
ALND should be performed during surgery.13,23,24 In the post-Z0011 period of the treatment of 222 
breast tumours, not only the presence of axillary metastasis is examined, but positive cases are 223 
also differentiated as mild (lymph node status N1 and 1 to 3 positive lymph nodes) and severe 224 
(lymph node status N2 and 4 or more positive lymph nodes) axillary metastases. Lim et al. 225 
confirmed that if the patient meets the criteria for the Z0011 study and the axillary ultrasound 226 
detects 3 or more positive lymph nodes, it is very likely that there are multiple positive lymph 227 
nodes in the axilla; therefore, ALND cannot be avoided.23 This result has also been confirmed 228 
by Liu et al., who found that ALND may be avoided if patients meet the Z0011 study criteria 229 
and the axillary ultrasound examination confirms only one suspected metastatic lymph node25. 230 
If two lymph nodes are considered metastatic based on an ultrasound examination, histological 231 
sampling and axillary lymph node dissection are recommended.  Liang et al. highlight the 232 
importance of a preoperative histological examination; the authors have shown that in cases 233 
where axillary lymph nodes are found to be positive with fine needle aspiration cytology, the 234 
patient is more likely to have more than 3 metastatic lymph nodes in the axilla, compared to 235 
cases where the sentinel lymph node biopsy confirms 1 to 2 metastatic lymph nodes.26 236 
In our study, we examined which combination of preoperative parameters would allow 237 
axillary lymph node dissection to be avoided if axillary lymph node involvement is confirmed 238 
preoperatively. We also examined which of these clinicopathological characteristics could 239 
eliminate the need for this radical surgical intervention. Based on our results, the severity of the 240 
involvement of the axillary region in the tumour process could not be clearly predicted 241 
preoperatively with the clinicopathological characteristics of the tumour in patients not 242 
receiving neoadjuvant therapy. In contrast, a recent study confirmed that primary ALND is not 243 
necessary and SLNB is recommended if the preoperative breast ultrasound confirms a 2-cm or 244 
smaller primary tumour in the breast, no more than one positive lymph node is confirmed with 245 
aspiration cytology, and the patient does not receive neoadjuvant therapy.13 In another 246 
retrospective study, Lloyd et al. also found that patients are very likely to have no more than 2 247 
axillary lymph nodes with macrometastasis if the preoperative ultrasound confirmed a 20-mm 248 
or smaller primary tumour, histology of this tumour confirmed invasive ductal or lobular 249 
carcinoma, and breast-conserving surgery was performed. Therefore, in these cases, ALND 250 
represents overtreatment.24  251 
Based on our study, we claim that lymph node status N0–1 in patients not receiving 252 
neoadjuvant therapy cannot be determined with certainty with preoperative examinations, while 253 
the lymph node status of patients receiving neoadjuvant chemotherapy can be predicted with 254 
great certainty based on the results of the preoperative ultrasound examination. If patients also 255 
receive neoadjuvant therapy, it can be predicted with high probability whether the disease is in 256 
stage N0–1 or not and whether ALND can be avoided or not based on the preoperative size of 257 
the tumour (<20 mm, p = 0.002) and the preoperative size of the lymph node (<5 mm, p = 0.04). 258 
In patients with breast tumours, the lymph node status of the axilla plays a key role in 259 
planning local and systemic therapy. If there is a metastatic lymph node in the axilla, a 260 
significant proportion of patients receive neoadjuvant systemic therapy, which resolves the 261 
axillary metastatic process in approximately 40% of cases.27 Following neoadjuvant therapy, 262 
the standard surgical procedure in these patients was ALND even in cases with complete 263 
pathological remission. Several studies have addressed the question of sentinel lymph node 264 
biopsy and repeated biopsy after neoadjuvant therapy.28 In the ACOSOG Z1071 study, the rate 265 
of false negative sentinel lymph node biopsies was close to 10% false negative (12.6%), and 266 
this value further decreased with the removal of the lymph node indicated with a marker (metal 267 
clip) during axillary core biopsy. During surgical intervention, the SLN is already detected 268 
using the classical dual tracer method (technetium 99m-labelled human colloidal albumin and 269 
blue dye). With this technique (targeted axillary dissection, TAD), the rate of false negative 270 
sentinel lymph nodes decreased to approximately 2%.29,30,27,31 Pilewski et al. analysed data from 271 
425 patients and studied the extent to which preoperative imaging studies influence the lymph 272 
node status of the axilla.32,33 If the examinations suggested the presence of a metastatic lymph 273 
node and the patient met the criteria for the Z0011 study, axillary lymph node dissection could 274 
have been avoided in 71% of cases. If aspiration cytology was positive, ALND was unnecessary 275 
in 45% of cases. A Spanish study published in 2018 also investigated whether axillary lymph 276 
node dissection should be performed after neoadjuvant therapy in cases where an axillary lymph 277 
node is considered positive with aspiration cytology.34 In cases showing a significant presence 278 
of the HER2 receptor and low expression of the oestrogen receptor, there is a high chance that 279 
complete pathological remission occurs, and in these cases, ALND was not recommended. Our 280 
analyses confirmed the same result. Following neoadjuvant therapy, no more than 3 and no 281 
more than 2 positive lymph nodes were confirmed, respectively, with the final histology in two-282 
thirds (40/59, 68%) and in over 50% (34/59, 57%) of the cases, respectively; therefore, axillary 283 
lymph node dissection could have been avoided. 284 
Data from 3398 patients were reviewed in a meta-analysis, and the authors aimed to see 285 
whether ALND is necessary after neoadjuvant therapy in lymph node-positive breast tumour 286 
cases.10 According to the analysis, the recommended treatment strategy at present is ALND. 287 
However, optimizing preoperative examinations and screening the patient population may help 288 
to achieve a more precise preoperative evaluation of axillary lymph node status. In the future, 289 
performing SLN with the dual tracer method and labelling the positive axillary lymph node in 290 
advance with a metal clip or with a radiopharmaceutical containing iodine followed by 291 
removing the labelled lymph node may decrease the number of axillary lymph node dissections. 292 
Based on the analysis, HER2-positive and triple receptor-negative cases by immunochemistry 293 
require further research. A study published in 2017 showed that the efficacy of neoadjuvant 294 
therapy did not differ in these cases, but further studies are recommended in these cases as 295 
well.11 Our study also showed no correlation between the lymph node status and the 296 
immunochemical status of the tumour. The same result was found in a study; ALND could be 297 
avoided after neoadjuvant therapy in 48% of the patients, especially in the case of HER2 298 
receptor-positive and triple receptor-negative cases. The study supported performing SLNB in 299 
patients with a breast tumour receiving neoadjuvant therapy and with multiple axillary lymph 300 
node metastases as well. Longer studies are required to support the results.12 A retrospective 301 
study that processed data from 1944 patients confirms this result; the study concluded that if 302 
patients receive neoadjuvant therapy followed by a mastectomy and if the receptor status is 303 
HER2-positive and triple receptor-negative, ALND could most likely have been avoided.35 304 
 305 
Conclusions 306 
Our results show that detecting suspicious lymph nodes by axillary ultrasound 307 
examination may predict the stage of the disease; therefore, we consider a complete 308 
examination of the axilla important in ruling out potential lymph node metastases. Our results 309 
confirm that in patients receiving neoadjuvant therapy, in addition to the preoperative size of 310 
the tumour (<20 mm, p = 0.002), the preoperative size of the lymph node (<15 mm, p = 0.04) 311 
may also be used to predict that the stage of the disease is N0–1. In these cases, sentinel lymph 312 
node biopsy with or without radiation therapy and close follow-up may serve as adequate 313 
therapy.  314 
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  523 
Tables 524 
 525 
Table 1. 526 
Relation of preoperative imaging results to final lymph node disease burden in patients not 527 
receiving neoadjuvant therapy – I – Chi square test 528 
 529 
Neoadj. 0 N0–1 (n=76) N2–3 (n=55) p value 
Tumour size on imaging n=76 n=55 0.703 
≤20mm 44 (57.9%) 30 (54.5%)   
>20mm 32 (42.1%) 25 (45.5%)   
Tumour size on imaging (TNBC) n=19 n=12 0.981 
≤20mm 11 (57.9%) 7 (58.3%)   
>20mm 8 (42.1%) 5 (41.7%)   
Lymph node size on imaging n=68 n=48 0.979 
≤15mm 31 (45.6%) 22 (45.8%)   
>15mm 37 (54.4%) 26 (54.2%)   
Lymph node size on imaging (TNBC) n=17 n=11 0.453 
≤15mm 7 (41.17%) 3 (27.27%)   
>15mm 10 (58.83%) 8 (72.73%)   
Tumour ≤20mm and lymph node ≤15mm n=31 n=22 0.948 
Number of abnormal lymph nodes on 
axillary ultrasound 
n=76 n=55 0.338 
1 65 (85.53%) 43 (78.18%)   
>1 11 (14.47%) 12(21.82%)   
  530 
Table 2.   531 
Relation of preoperative pathological factors to final lymph node disease burden in patients 532 
not receiving neoadjuvant therapy – II – Chi square test 533 
 534 
Neoadj. 0 N0–1 (n=76) N2–3 (n=55) p value 
ER n=76 n=55 0.281 
positive 47 (61.84%) 39 (70.91%)   
negative 29 (38.16%) 16 (29.09%)   
PR n=76 n=55 0.305 
positive 43 (56.58%) 36 (65.45%)   
negative 33 (43.42%) 19 (34.55%)   
Ki67 n=76 n=55 0.845 
positive 64 (84.21%) 47 (85.45%)   
negative 12 (15.79%) 8 (14.55%)   
Topoiz. n=76 n=55 0.883 
positive 60 (78.95%) 44 (80%)   
negative 16 (21.05%) 11 (20%)   
HER-2 n=76 n=55 0.883 
positive 16 (21.05%) 11 (20%)   
negative 60 (78.95%) 44 (80%)   
TNBC n=76 n=55 0.672 
yes 19 (25%) 12 (21.8%)   
no 57 (75%) 43 (78.2%)   
Tumour histology on biopsy n=76 n=55 0.871 
Ductal 48 (63.16%) 33 (60%)   
Lobular 4 (5.26%) 4 (7.27%)   
Other invasive 24 (31.58%) 18 (32.73%)   
Histologic grade n=65 n=51 0.576 
I 2 (3.08%) 3 (5.88%)   
II 27 (41.54%) 24 (47.06%)   
III 36 (55.38%) 24 (47.06%)   
  535 
Table 3.  536 
Relation of preoperative imaging results to final lymph node disease burden in patients 537 
receiving neoadjuvant therapy – I – Chi square test 538 
 539 
Neoadj. N0–1 (n=40) N2–3 (n=19) p value 
Tumour size on imaging n=40 n=19 0.002 
≤20mm 28 (70%) 5 (26.32%)   
>20mm 12 (30%) 14 (73.68%)   
Tumour size on imaging (TNBC) n=16 n=7 <0.001 
≤20mm 14 (87.5%) 0 (0%)   
>20mm 2 (12.5%) 7 (100%)   
Lymph node size on imaging n=31 n=13 0.04 
≤15mm 20 (64.51%) 4 (30.77%)   
>15mm 11 (35.49%) 9 (69.23%)   
Lymph node size on imaging (TNBC) n=12 n=6 0.737 
≤15mm 5 (41.67%) 3 (50%)   
>15mm 7 (58.33%) 3 (50%)   
Tumour ≤20mm and lymph node ≤15mm n=20 n=4 0.01 
Number of abnormal lymph nodes on 
axillary ultrasound 
n=40 n=19 0.161 
1 38 (95%) 15 (78.95%)   
>1 2 (5%) 4 (21.05%)   
  540 
Table 4.  541 
Relation of preoperative pathological factors to final lymph node disease burden in patients 542 
receiving neoadjuvant therapy – II – Chi square test 543 
 544 
Neoadj. N0–1 (n=40) N2–3 (n=19) p value 
ER n=40 n=19 0.361 
positive 16 (40%) 10 (52.63%)   
negative 24 (60%) 9 (47.37%)   
PR n=40 n=19  0.432 
positive 7 (17.5%) 5 (26.32%)   
negative 33 (82.5%) 14 (73.68%)   
Ki67 n=40 n=19 0.551 
positive 31 (77.5%) 16 (84.22%)   
negative 9 (22.5%) 3 (15.78%)   
Topoiz. n=40 n=19 0.305 
positive 24 (60%) 14 (73.68%)   
negative 16 (40%) 5 (26.32%)   
HER-2 n=40 n=19 0.323 
positive 11 (27.5%) 3 (15.78%)   
negative 29 (72.5%) 16 (84.22%)   
TNBC n=40 n=19 0.816 
yes 16 (40%) 7 (36.84%)   
no 24 (60%) 12 (63.16%)   
Tumour histology on biopsy n=40 n=19 0.314 
Ductal 29 (72.5%) 14 (73.69%)   
Lobular 0 (0%) 1 (5.26%)   
Other invasive 11 (27.5%) 4 (21.05%)   
Histologic grade n=32 n=18 0.157 
I 5 (15.62%) 0 (0%)   
II 12 (37.5%) 6 (33.33%)   
III 15 (46.88%) 12 (66.67%)   
  545 
Table 5. 546 
Result of logistic regression 547 
 548 
Variables Sig Exp(B) 95% CI for EXP(B) 
   Lower Upper 
Tumour size 0.004 1.050 1.016  1.085 
  549 
Table 6. 550 
Relation of imaging results to modified final lymph node disease burden (Z1 or Z2) in 551 
patients receiving neoadjuvant therapy – I – Chi square test 552 
 553 
Neoadj. Z1 (n=34) Z2 (n=25) p value 
Tumour size on imaging n=34 n=25 0.008 
≤20mm 24 (70.58%) 9 (36%)   
>20mm 10 (29.42%) 16 (64%)   
Tumour size on imaging (TNBC) n=14 n=9 0.002 
≤20mm 12 (85.71%) 2 (22.22%)   
>20mm 2 (14.29%) 7 (77.78%)   
Lymph node size on imaging n=28 n=16 0.086 
≤15mm 18 (64.29%) 6 (37.5%)   
>15mm 10 (35.71%) 10 (62.5%)   
Lymph node size on imaging (TNBC) n=11 n=7 0.914 
≤15mm 5 (45.45%) 3 (42.86%)   
>15mm 6 (54.55%) 4 (57.14%)   
Tumour ≤20mm and lymph node 
≤15mm 
n=18 n=6 0.017 
Number of abnormal lymph nodes on 
axillary ultrasound 
n=34 n=25 0.177 
1 33 (97.06%) 20 (80%)   
>1 1 (2.94%) 5 (20%)   
 554 
